Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Interest & Investment Income (2016 - 2017)

Syndax Pharmaceuticals (SNDX) has 3 years of Interest & Investment Income data on record, last reported at $462000.0 in Q4 2017.

  • For Q4 2017, Interest & Investment Income rose 72.39% year-over-year to $462000.0; the TTM value through Dec 2017 reached $1.4 million, up 48.64%, while the annual FY2025 figure was $22.7 million, 12.88% down from the prior year.
  • Interest & Investment Income reached $462000.0 in Q4 2017 per SNDX's latest filing, up from $410000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $462000.0 in Q4 2017 and bottomed at -$524000.0 in Q4 2015.
  • Average Interest & Investment Income over 3 years is $80250.0, with a median of $263500.0 recorded in 2016.
  • Peak YoY movement for Interest & Investment Income: surged 217.03% in 2016, then increased 5.07% in 2017.
  • A 3-year view of Interest & Investment Income shows it stood at -$524000.0 in 2015, then skyrocketed by 151.15% to $268000.0 in 2016, then skyrocketed by 72.39% to $462000.0 in 2017.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $462000.0 in Q4 2017, $410000.0 in Q3 2017, and $290000.0 in Q2 2017.